Streetbeat News

Earnings

STZ

Constellation Brands' shares surged following the announcement of Q4 financial results that exceeded expectations, along with FY25 adjusted EPS guidance surpassing estimates.

Portfolio Pulse from Benzinga Newsdesk

April 11, 2024 | 11:50 am

STZ

Constellation Brands projects its adjusted earnings per share (EPS) for fiscal year 2025 to be between $13.50 and $13.80, surpassing the estimated $13.44.

Portfolio Pulse from Benzinga Newsdesk

April 11, 2024 | 11:37 am

STZ

Constellation Brands (NYSE:STZ) reported Q4 adjusted EPS of $2.30, surpassing the $2.08 estimate, and sales of $2.14B, exceeding the $2.10B estimate. This represents a 16.16% increase in EPS and a 7.06% increase in sales from the same period last year.

Portfolio Pulse from Benzinga Newsdesk

April 11, 2024 | 11:33 am

ALPN

HOOD

QQQ

SPY

Wall Street anticipates a lower opening influenced by upcoming inflation data, central bank decisions, and Fed speeches. SPDR S&P 500 ETF Trust and Invesco QQQ ETF saw premarket declines. Analysts offer mixed views on market conditions, with some seeing buying opportunities amidst inflation concerns. Stocks like Robinhood and Alpine Immune Sciences are in focus due to an analyst downgrade and acquisition news, respectively. Economic data releases and Fed officials' speeches are also on investors' radar.

Portfolio Pulse from Shanthi Rexaline

April 11, 2024 | 11:27 am

BW

Babcock & Wilcox's shares are trading higher following the company's announcement of an increased adjusted EBITDA target for FY24.

Portfolio Pulse from Benzinga Newsdesk

April 11, 2024 | 11:20 am

RENT

Rent the Runway shares increased following mixed Q4 financial results and future guidance.

Portfolio Pulse from Benzinga Newsdesk

April 11, 2024 | 11:19 am

KMX

CarMax shares are trading lower following the announcement of Q4 FY24 earnings that fell short of expectations.

Portfolio Pulse from Benzinga Newsdesk

April 11, 2024 | 11:16 am

FUFU

BitFuFu shares are trading higher following the announcement of a 43.3% revenue growth for FY23.

Portfolio Pulse from Benzinga Newsdesk

April 11, 2024 | 11:16 am

EPRX

Eupraxia announced its participation in the Osteoarthritis Research Society International World Congress 2024, highlighting the potential of its EP-104IAR treatment. The Phase 2b SPRINGBOARD study of EP-104IAR met primary and key secondary endpoints, demonstrating significant pain reduction and a favorable safety profile, suggesting it could be a leading treatment for osteoarthritis, including in diabetic patients.

Portfolio Pulse from Benzinga Newsdesk

April 11, 2024 | 11:13 am

PSNY

Polestar anticipates its expanding luxury SUV lineup, including the Polestar 4's production shift to South Korea in H2 2025, to enhance revenue and margins, aligning with its 2025 financial goals. This move aims to boost profitability in crucial markets such as the US.

Portfolio Pulse from Benzinga Newsdesk

April 11, 2024 | 11:11 am